Patents Examined by Jae W Lee
-
Patent number: 11685916Abstract: The disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.Type: GrantFiled: May 13, 2020Date of Patent: June 27, 2023Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh, Soumya Kannan
-
Patent number: 11674127Abstract: A process of recovering oil, comprising (a) converting a starch-containing material into dextrins with an alpha-amylase; (b) saccharifying the dextrins using a carbohydrate source generating enzyme to form a sugar; (c) fermenting the sugar in a fermentation medium into a fermentation product using a fermenting organism; (d) recovering the fermentation product to form a whole stillage; (e) separating the whole stillage into thin stillage and wet cake; (e?) optionally concentrating the thin stillage into syrup; (f) recovering oil from the thin stillage and/or optionally the syrup, wherein a protease and a phospholipase are present and/or added during steps (a) to (c). Use of a protease and a phospholipase for increasing oil recovery yields from thin stillage and/or syrup in a fermentation product production process.Type: GrantFiled: May 3, 2021Date of Patent: June 13, 2023Assignee: NOVOZYMES A/SInventors: Joseph Jump, Nathaniel Edward Kreel, Bernardo Vidal, Jr., Chee-Leong Soong, Madison Roberts, Melissa Carrie Hooss, Xinyu Shen
-
Patent number: 11674129Abstract: The present invention relates to polypeptide, preferably to a glucose isomerase, comprising an amino acid sequence, wherein the amino acid sequence of the polypeptide, preferably the glucose isomerase, is at least 95% identical to an amino acid sequence of SEQ ID NO:1, wherein the amino acid sequence of the polypeptide, preferably the glucose isomerase, comprises an amino acid substitution at one or more amino acid positions, wherein the one or more amino acid positions is/are each and independently selected from the group consisting of SEQ ID NO: 1 amino acid positions 89, 90, 95, 0, 33, 34, 35, and 59. The present invention further relates to methods preparing glucose including the use of the polypeptides of the invention for preparing glucose.Type: GrantFiled: June 9, 2021Date of Patent: June 13, 2023Assignees: NEW MATTERHORN, LLC, C-LEcta GmbHInventors: Birgit Brucher, Andreas Vogel, Hanna Maria Dudek, Rico Czaja
-
Patent number: 11667934Abstract: Provided is a platform for expressing a protein of interest by artificially manipulating the liver, and more particularly, to a platform for alleviating or treating a genetic disorder or improving a body function by inducing expression by inserting a transgene (e.g., a therapeutic gene) which can function or be expressed normally, into a high-expression secretory gene, instead of a disease gene which functions or is expressed abnormally. The high-expression secretory gene includes the HP or APOC3 gene. The transgene includes one that is highly expressed using a promoter in a hepatocyte genome and is secretory out of the cell.Type: GrantFiled: June 15, 2018Date of Patent: June 6, 2023Assignee: TOOLGEN INCORPORATEDInventors: Seokjoong Kim, Dong Woo Song, Kyu Jun Lee, Jung-Min Lee, Un-Gi Kim
-
Patent number: 11661617Abstract: Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.Type: GrantFiled: September 4, 2020Date of Patent: May 30, 2023Assignee: Compass Pathfinder LimitedInventor: Ryan Protzko
-
Patent number: 11655270Abstract: The present invention relates to a method for extracting collagen from a liposuction effluent, wherein collagen is extracted by treating a collagen-containing liposuction effluent in the presence of a supercritical fluid. According to the present invention, conventionally discarded collagen in a liposuction effluent can be extracted at high purity, and the extracted high purity collagen can be widely used in medical, pharmaceutical, and cosmetic products.Type: GrantFiled: August 8, 2017Date of Patent: May 23, 2023Assignee: DOF INC.Inventors: YongWoo Shin, Hyoung Soon Kim, Yoonkook Park, Yong-Soo Choi, Kyu-byung Kim, Seong Sik You, Gapsu Han, Seong-Rae No
-
Patent number: 11649471Abstract: The present invention relates to a process for the production of one or more fermentation product from a sugar composition, comprising the following steps: a) fermentation of the sugar composition in the presence of a yeast belonging to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces or Yarrowia: and b) recovery of the fermentation product, wherein the yeast comprises the genes araA, araB and araD and the sugar composition comprises glucose, galactose and arabinose.Type: GrantFiled: March 12, 2021Date of Patent: May 16, 2023Assignee: DSM IP ASSETS B.V.Inventors: Paul Klaassen, Gijsberdina Pieternella Van Suylekom, Bianca Elisabeth Maria Gielesen, Nicolette Jasmijn Broers, Beate Wiedemann, Wilhelmus Theodorus Antonius Maria De Laat
-
Patent number: 11643676Abstract: The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.Type: GrantFiled: April 8, 2021Date of Patent: May 9, 2023Assignee: Design-Zyme LLCInventors: Peter Albert Petillo, Dwight O'Dell Deay, III, Michael Gregory Branden
-
Patent number: 11639499Abstract: The present invention provides MMLV reverse transcriptase enzymes with increased thermal stability as compared with wild type MMLV and AMV reverse transcriptases. The improved thermal stability allows for reverse transcription of RNA to cDNA at temperatures above 37° C., thereby reducing error rates introduced during cDNA synthesis. As a result, the reverse transcriptases of the invention allow for increased accuracy in the determination of transcriptomes of living organisms.Type: GrantFiled: September 8, 2022Date of Patent: May 2, 2023Assignee: Watchmaker Genomics, Inc.Inventors: Julie Walker, Bjarne Faurholm, Ross Wadsworth, Brian A. Kudlow
-
Patent number: 11639395Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.Type: GrantFiled: November 2, 2020Date of Patent: May 2, 2023Assignee: Genentech, Inc.Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
-
Patent number: 11639520Abstract: The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula I, wherein Formula I in the 5?-to-3? direction comprises: A-(B-L)J-C-M-T-D; wherein A is 0-15 nucleotides in length; B is 4-12 nucleotides in length; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)J-C and T-D are separate nucleic acid strands; T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.Type: GrantFiled: July 9, 2022Date of Patent: May 2, 2023Assignee: LabSimply, Inc.Inventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey, Rashid Bashir
-
Patent number: 11629342Abstract: The present disclosure provides methods and compositions of modulating expression of a target nucleic acid in a eukaryotic cell. The methods include providing to the cell a guide RNA complementary to the target nucleic acid sequence, providing to the cell a fusion protein, wherein the fusion protein comprises a nuclease null Cas9 protein and a transcriptional effector domain, wherein the nuclease null Cas9 protein interacts with the guide RNA and binds to the target nucleic acid sequence in a site specific manner and wherein the transcriptional effector domain modulates expression of the target nucleic acid.Type: GrantFiled: October 17, 2018Date of Patent: April 18, 2023Assignee: President and Fellows of Harvard CollegeInventors: Alejandro Chavez, Nan Cher Yeo
-
Patent number: 11618896Abstract: The disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.Type: GrantFiled: September 21, 2018Date of Patent: April 4, 2023Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENTAND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh, Soumya Kannan
-
Patent number: 11608364Abstract: The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polypeptide when measured under the same conditions.Type: GrantFiled: April 29, 2019Date of Patent: March 21, 2023Assignee: DSM IP ASSETS B.V.Inventors: Johannes Gustaaf Ernst Van Leeuwen, Viktor Marius Boer, Priscilla Zwartjens, Jos Van Vugt, René Marcel De Jong
-
Patent number: 11602581Abstract: A three-dimensional hydrogel scaffold of the present invention contains a cell to be transplanted in vivo and comprises a first hydrogel block on which a plurality of holes are formed and one or more second hydrogel blocks which are assembled to the holes and are biodegradable. A large hydrogel scaffold can be prepared by means of the assembly of the blocks. The survivability of the cell being transplanted is high and the biodegradability of the blocks varies, and thus the risk of hypoxia is reduced.Type: GrantFiled: September 27, 2018Date of Patent: March 14, 2023Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITYInventors: Dong Yun Lee, Seon Jae Lee
-
Patent number: 11597750Abstract: The present invention is directed to a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of preparing a solution of a silk fusion protein in an aqueous medium and concentrating the silk fusion protein in the aqueous medium, wherein the fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences, such as cellulose binding modules, SpyCatcher domains, tenth type III module of Fibronectin, gamma-crystallin D, flanking the silk-like protein sequence; wherein the method is performed so that the silk fusion protein is not precipitated and subsequently dissolved to the aqueous medium. The present invention is also directed to using such fusion proteins as adhesives.Type: GrantFiled: June 13, 2018Date of Patent: March 7, 2023Assignee: Aalto University Foundation srInventors: Markus Linder, Pezhman Mohammadi, Sesilja Aranko
-
Patent number: 11597919Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.Type: GrantFiled: October 3, 2019Date of Patent: March 7, 2023Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, UNIVERSITY OF TOKYOInventors: Silvana Konermann, Alexandro Trevino, Mark Brigham, Fei Ran, Patrick Hsu, Chie-yu Lin, Osamu Nureki, Hiroshi Nishimasu, Ryuichiro Ishitani, Feng Zhang
-
Patent number: 11597947Abstract: Provided is a method of inserting a polynucleotide sequence into a genome of a cell. The method comprises: generating a double-strand break at a target site of the genome; and introducing into the cell a virus. The virus comprises a nucleic acid comprising the polynucleotide sequence to be inserted or the complementary sequence thereof. The nucleic acid does not comprise a homologous arm or comprises very short (5˜25 bp) homologous arms corresponding to the target site. Also provided herein is a composition for inserting a polynucleotide sequence into a genome of a cell. The composition comprises a site-specific nuclease capable of generating a DNA double-strand break at a target site of the genome and a virus comprising a nucleic acid comprising the polynucleotide sequence or the complementary sequence thereof.Type: GrantFiled: December 29, 2017Date of Patent: March 7, 2023Assignee: ASC THERAPEUTICS INC.Inventors: Ling-Jie Kong, Mi Shi, Hainan Chen, Ruby Yanru Tsai
-
Patent number: 11578311Abstract: The present application relates to the identification of novel DNA methyltransferases including CHG methylation in algal species. The present application relates to algal mutants permitting the expression of exogenous genes by alleviating the epigenetic mechanisms of CHG and CHH methylation of exogenous DNA and mono- and tri-methylation of lysine 9 of histone 3 (H3K9). This is achieved by mutating or attenuating the methyltransferase (MTase) genes in algae. The present application also relates to methods for efficiently expressing exogenous genes in algal species.Type: GrantFiled: December 12, 2019Date of Patent: February 14, 2023Assignee: Viridos, Inc.Inventors: June Elizabeth Pais, Roberto Spreafico
-
Patent number: 11572564Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.Type: GrantFiled: February 8, 2016Date of Patent: February 7, 2023Assignee: Genomatica, Inc.Inventor: Wei Niu